Skip to main content

Esophagogastric Cancer clinical trials at University of California Health

1 research study open to eligible people

Showing trials for
  • Amivantamab in People with Esophagogastric Cancer

    open to eligible people ages 18 years and up

    The purpose of this study is to see whether the study drug, amivantamab, is an effective treatment for people with EGFR- or MET-amplified esophagogastric cancer. The researchers will also look at whether amivantamab is a safe treatment that causes few or mild side effects in participants.

    at UC Irvine

Last updated: